Last reviewed · How we verify
NCT06716671: Glucocavi
Influence of Continuous Glucose Monitoring on Quality of Life in People With Type 2 Diabetes Mellitus
trial in Continuous Glucose Monitoring in 55 participants. Participants enrolled and being followed up; not accepting new ones.
31 May 2026
Quick facts
| Lead sponsor | Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 55 |
| Start date | 4 September 2024 |
| Primary completion | 31 May 2026 |
| Estimated completion | 31 May 2026 |
| Sites | 1 location across Spain |
Conditions studied
- Continuous Glucose Monitoring — all drugs for Continuous Glucose Monitoring →
- Quality of Life — all drugs for Quality of Life →
- Type 2 Diabetes Mellitus (T2DM) — all drugs for Type 2 Diabetes Mellitus (T2DM) →
Sponsor
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina — full company profile →
Who can join
18 and older, any sex, with Continuous Glucose Monitoring or Quality of Life. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: Diabetes Mellitus (DM) is a chronic disease that affects millions of people worldwide. More than 95% of cases are type 2 diabetes mellitus (T2DM). In recent years, diabetes management has evolved with the introduction of continuous glucose monitoring (CGM) devices. These devices implanted under the skin allow continuous measurement of glucose levels monitoring glucose trends and the rate at which glucose level rise and fall without the need for capillary glycaemias test. While studies demostrate the effectiveness of CGM devices in controlling glucose levels in adults with T2DM, there is no evidence related to quality of life in this patients. Hypothesis: The use of CGM in people with T2DM improves their quality of life, reduces distress about the disease, reduces fear of hypoglycaemia, increases detection of hypoglycaemia, and improves metabolic control. Objectives: To assess quality of life, diabetes distress, fear of hypoglycaemia, detection of hypoglycaemia, and metabolic control in people with T2DM before and after the use of CGM sensors. Methodology: Prospective observational pre-post unblinded study. Adults with type 2 diabetes using a CGM device in the primary care setting will be followed for 12 months. They will be asked to complete 5 questionnaires at baseline, and 4 questionnaires at 3, 6 and 12 months. No other activity that differs from usual clinical practice will be performed. Data analysis: a descriptive analysis of the main study variables will be carried out and the differences in the data before and after the intervention will be analysed using the chi-square test for qualitative variables, and the Student's t-test for quantitative variables. Statistical significance will be accepted at a p-value \< 0.05. Applicability and relevance: The results of the study will provide information on whether CGM devices improve quality of life and glycaemic control in people with type 2 diabetes. With these results it will be possible to assess whether it is beneficial to extend funding for CGM devices to more of the population than is currently the case.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06716671
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Continuous Glucose Monitoring
Currently open trials in the same condition.
- NCT07097415 — The Application of Continuous Blood Glucose Monitoring in Optimizing the Management of Type 2 Diabetes · NA · recruiting
- NCT06648174 — The Project for Managing Cardiometabolic Risk in Women Diagnosed With Gestational Diabetes Mellitus · NA · recruiting
- NCT06641765 — Continuous Glucose Monitoring in Dialysis Patients With Diabetes · NA · active not recruiting
- NCT06436326 — The Impact of Continuous Glucose Monitoring on Maternal and Infant's Outcomes in Gestational Diabetes · NA · recruiting
- NCT05337098 — Non-Nutritive Sweetener Consumption and Glucose Homeostasis in Older Adults With Prediabetes · NA · recruiting
Other Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina trials
Trials by the same sponsor.
- NCT07441759 — throMboembolic Risk Associated To High atrIal Fibrillation riSk · not yet recruiting
- NCT07132632 — Effect of a Multicomponent Therapeutic Exercise Program in Primary Care on Frailty and Sarcopenia in Older Adults · NA · not yet recruiting
- NCT07373119 — Improving Frailty in Patients With Stable Ischemic Heart Disease · NA · enrolling by invitation
- NCT06581367 — Tailoring Antibiotic Duration for Respiratory Tract Infections in Primary Care · Phase 4 · not yet recruiting
- NCT06988904 — ENERGY2MOB STUDY: OBESITY MANAGEMENT IN BERGUEDÀ · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06716671 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
- Last refreshed: 2 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06716671.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing